Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme class drugs
4 results
Aldurazyme (laronidase)
(laronidase)Genzyme Corporation
Usage: ALDURAZYME® is indicated for treating adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), and for those with moderate to severe symptoms of the Scheie form. Its safety and effectiveness in mildly affected Scheie patients and CNS effects are not established.
Elaprase (idursulfase)
(idursulfase)Takeda Pharmaceuticals America, Inc.
Usage: ELAPRASE is indicated for patients with Hunter syndrome (MPS II), improving walking capacity in those aged 5 and older. For patients 16 months to 5 years, it has shown reduced spleen volume but lacks data on clinical outcomes. Safety is unestablished for children under 16 months.
Naglazyme (galsulfase)
(galsulfase)BioMarin Pharmaceutical Inc.
Usage: NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) and has demonstrated effectiveness in improving walking and stair-climbing capabilities.
Vimizim (elosulfase alfa)
(elosulfase alfa)BioMarin Pharmaceutical Inc.
Usage: Vimizim (elosulfase alfa) is indicated for the treatment of patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).